Structure-activity relationships for 4-anilinoquinazolines as potent inhibitors at the ATP binding site of the epidermal growth factor receptor in vitro

Clinical and Experimental Pharmacology and Physiology

Volumn 23, Issue 5, 1996, Pages 424-427

  Denny, William A ^b   Rewcastle, Gordon W ^b   Bridges, Alexander J ^a   Fry, David W ^a   Kraker, Alan J ^a  

^a PFIZER INC   (United States)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

4 Anilinoquinazoline; Enzyme inhibitor; Epidermal growth factor receptor; Growth signal transduction

Indexed keywords

4 ANILINOQUINAZOLINE DERIVATIVE; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE; QUINAZOLINE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG DEVELOPMENT; HUMAN; HUMAN CELL; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; TUMOR GROWTH;

EID: 0030013302     PISSN: 03051870     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1681.1996.tb02752.x     Document Type: Article

References (20)

1. Fantl WJ, Johnson DE, Williams LT. Signalling by receptor tyrosine kinases. Annu. Rev. Biochem. 1993; 62: 453-81.
2. Workman P. The potential for molecular oncology to define new drug targets. In: Kerr DJ, Workman P (eds). New Molecular Targets for Cancer Chemotherapy. CRC Press, Boca Raton. 1994; Ch. 1.
3. Hayman MJ, Enrietto PJ. Cell transformation by the epidermal growth factor receptor and v-erbB. Cancer Cells 1991; 3: 302-7.
4. Dobrusin EM, Fry DW. Protein tyrosine kinases and cancer. Annu. Rep. Med. Chem. 1992; 27: 169-78.
5. Jardines L, Weiss M, Fowble B, Greene M. Neu (c-erbB-2/HER2) and the epidermal growth factor receptor (EGFR) in breast cancer. Pathobiology 1993; 61: 268-82.
6. Lupu R, Lipmann ME. The role of erbB-2 signal transduction pathways in human breast cancer. Breast Cancer Res. Treat. 1993; 27: 83-93.
7. Burke TR. Protein-tyrosine kinase inhibitors. Drugs Future 1992; 17: 119-31.
8. Chang C-J, Geahlen RL. Protein-tyrosine kinase inhibition: Mechanism-based discovery of antitumor agents. J. Nat. Prod. 1992; 55: 1529-60.
9. Levitzki A. Tyrphostins: Tyrosine kinase blockers as novel antiproliferative agents and dissectors of signal transduction. FASEB J. 1992; 6: 3275-82.
10. Rewcastle GW, Palmer BD, Dobrusin EM, Fry DW, Kraker AJ, Denny WA. Tyrosine kinase inhibitors. 3. Structure-activity relationships for inhibition of protein tyrosine kinases by nuclear-substituted derivatives of 2,2′-dithiobis(1-methyl-N-phenyl-1H-indole-3-carboxamide). J. Med. Chem. 1994; 37: 2033-42.
11. v-src protein tyrosine kinases. J. Med. Chem. 1994; 37: 598-609.
12. Hanks SK, Quinn AM, Hunter T. The protein kinase family: Conserved features and phylogeny of the catalytic domains. Science 1988; 241: 42-52.
13. Geissler JF, Roesel JL, Meyer T, Trinks UP, Traxler P, Lydon NB. Benzopyranones and benzothiopyranones: A class of tyrosine kinase inhibitors with selectivity for the v-abl kinase. Cancer Res. 1992; 52: 4492-8.
14. Trinks U, Buchdunger E, Furet P et al. Dianilinophthalimides: Potent and selective, ATP-competitive inhibitors of the EGF-receptor protein tyrosine kinase. J. Med. Chem. 1994; 37: 1015-27.
15. Fry DW, Kraker AJ, McMichael A et al. A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science 1994; 265: 1093-5.
16. Ward WHJ, Cook PN, Slater AM, Davies DH, Holdgate GA, Green LR. Epidermal growth factor receptor tyrosine kinase. Investigation of catalytic mechanism, structure-based searching and discovery of a potent inhibitor. Biochem. Pharmacol. 1994; 48: 659-66.
17. Bridges AJ, Zhou H, Cody DR et al. Tyrosine kinase inhibitors. 8. An unusually steep structure activity relationship for analogues of 4-(3-bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor. J. Med. Chem. 1996; 39: 267-76.
18. Rewcastle GW, Denny WA, Zhou H et al. Tyrosine kinase inhibitors. 5. Synthesis and structure-activity relationships for 4-(phenylmethyl)amino- and 4-phenylaminoquinazolines as potent adenosine 5′-triphosphate binding site inhibitors of the tyrosine kinase domain of epidermal growth factor receptor. J. Med. Chem. 1995; 38: 3482-7.
19. Takase Y, Saeki T, Wanatabe N, Adachi H, Souda S, Saito I. Cyclic GMP phosphodiesterase inhibitors. 2. Requirement of 6-substitution of quinazoline derivatives for potent and selective inhibitory activity. J. Med. Chem. 1994; 37: 2106-11.
20. Maguire MP, Sheets KR, McVety K, Spada AP, Zilberstein A. A new series of PDGF receptor tyrosine kinase inhibitors; 3-substituted quinoline derivatives. J. Med. Chem. 1994; 37: 2129-37.